Not yet recruiting

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

By April 24, 2017 No Comments


Esophageal Neoplasms|Lung Neoplasms|Mesothelioma|Thymus Neoplasms|Neoplasms, Germ Cell and Embryonal

Estimated Enrollment: 100

Age Group: 18 Years to 100 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment

Study ID Numbers: 160152|16-C-0152

Study First Received: August 6, 2016

Last Updated: April 20, 2017

Estimated Primary Completion Date: August 3, 2028


Primary Outcome Measures:

Maximum tolerated dose|Overall response rate

Sponsors and Collaborators:

National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)

Website Link:

Leave a Reply

Call Now ButtonCall Now